Last $46.35 USD
Change Today +0.17 / 0.37%
Volume 151.3K
IART On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:46 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

integra lifesciences holding (IART) Snapshot

Open
$45.31
Previous Close
$46.18
Day High
$46.60
Day Low
$45.07
52 Week High
03/11/14 - $49.99
52 Week Low
07/19/13 - $36.93
Market Cap
1.5B
Average Volume 10 Days
155.3K
EPS TTM
$1.76
Shares Outstanding
32.6M
EX-Date
--
P/E TM
26.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for INTEGRA LIFESCIENCES HOLDING (IART)

Related News

No related news articles were found.

integra lifesciences holding (IART) Related Businessweek News

No Related Businessweek News Found

integra lifesciences holding (IART) Details

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in five segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. Its orthopedics products include specialty metal implants for surgery of the extremities, shoulder, and spine; orthobiologic products for repair and grafting of bone, including demineralized bone products, collagen ceramic matrices, and synthetic bone grafting solutions; dermal regeneration products and tissue-engineered wound dressings; and nerve and tendon repair products. The company also offers spinal fusion technologies comprising integrated interbody fusion devices, minimally invasive solutions, and deformity correction products; and neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. In addition, it provides extremity products, including bone and joint fixation devices, implants and instruments for osteoarthritis, rheumatoid arthritis, wrist and shoulder arthroplasty, carpal tunnel syndrome, and cubital tunnel syndrome, as well as regenerative medicine devices for the treatment of acute and chronic wounds, peripheral nerve repair and protection and tendon repair, and bone graft substitutes. Further, the company offers instruments products, such as specialty and general surgical and dental instruments; and surgical lighting for hospitals, outpatient surgery centers, and physician, veterinarian, and dental practices. Integra LifeSciences Holdings Corporation sells its products directly through various sales forces and distribution channels in the United States and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.

3,300 Employees
Last Reported Date: 02/27/14
Founded in 1989

integra lifesciences holding (IART) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $787.1K
President of Global Spine & Orthobiologics, H...
Total Annual Compensation: $336.6K
President of Neurosurgery and Corporate Vice ...
Total Annual Compensation: $335.1K
Corporate Vice President and President of Adv...
Total Annual Compensation: $318.6K
Chief Administrative Officer and Corporate Vi...
Total Annual Compensation: $549.4K
Compensation as of Fiscal Year 2013.

integra lifesciences holding (IART) Key Developments

Integra LifeSciences Holdings Corporation Announces Renewal and Extension of Credit Facility

Integra LifeSciences Holdings Corporation announced that it has established new terms under its credit facility, including an increase in the size of the facility and an extended maturity date, with its bank group led by Bank of America, N.A. and Wells Fargo Bank. The Company does not expect this renewal and extension in maturity to have a material impact on 2014 financial performance. The new credit facility, which amended and replaced the prior one, includes the following terms: An increase in the credit facility from $600 million to $900 million, consisting of a $750 million revolver and a term loan of $150 million; No change in pricing terms or commitment fees to the existing facility; An option to increase the aggregate size of the facility by $200 million with additional commitments; and, An extension of the current credit facility's maturity date to July 2, 2019. Integra plans to use the new credit facility to refinance the Company's borrowings under its existing facility, and for future acquisitions and general corporate purposes.

Integra LifeSciences Holdings Corporation Enters into Amended and Restated Credit Agreement

On July 2, 2014, Integra LifeSciences Holdings Corporation entered into an amended and restated credit agreement with a syndicate of lending banks, Bank of America, N.A., as Administrative Agent, Swing Line Lender and L/C Issuer, Wells Fargo Bank, National Association, as Syndication Agent and HSBC Bank USA, National Association, Royal Bank of Canada, Citizens Bank, National Association, DNB Capital LLC, Credit Agricole-Corporate and Investment Bank and TD Bank, N.A., as Co-Documentation Agents. The Amendment and Restatement creates an aggregate principal amount of up to $900 million available to the Company through the following facilities: (i) a $750 million revolving credit facility (increased from $600 million), which includes a $60 million sublimit for the issuance of standby letters of credit and a $60 million sublimit for swingline loans and (ii) a $150 million term loan facility. The Amendment and Restatement allows the Company to further increase the size of either the revolving credit facility or the term loan facility, or a combination thereof, by an aggregate of $200 million with additional commitments. The Amendment and Restatement extends the credit facility's maturity date from June 8, 2016 to July 2, 2019.

Integra LifeSciences Holdings Corporation Announces Three-Year Group Purchasing Contract with Premier, Inc

Integra LifeSciences Holding Corporation announced that its Orthopedics and Tissue Technologies group signed a three-year group purchasing contract with Premier Inc. The agreement will offer small bone orthopedic implants to Premier alliance members. The new contract allows Integra to meet Premier's needs in this area, and expands a rich Enterprise relationship while delivering broader access to its full portfolio, benefitting Premier alliance member healthcare organizations and their patients. This agreement is a first step in Integra's Enterprise Selling efforts to develop larger enterprise agreements to support the company's future growth plans over the next five years, and represents the Company's first agreement of this type.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IART:US $46.35 USD +0.17

IART Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chemed Corp $96.26 USD +1.16
CONMED Corp $44.31 USD +0.75
Masimo Corp $24.33 USD -0.07
NuVasive Inc $35.48 USD +0.96
Wright Medical Group Inc $31.16 USD -0.15
View Industry Companies
 

Industry Analysis

IART

Industry Average

Valuation IART Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 2.2x
Price/Cash Flow 437.7x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEGRA LIFESCIENCES HOLDING, please visit www.integralife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.